FDA to discuss Abbott's Humira for UC

FDA's Gastrointestinal Drugs Advisory Committee will meet on Aug. 28 to discuss an sBLA from Abbott Laboratories (NYSE:ABT) for Humira adalimumab to treat moderately to severely active ulcerative colitis in adults who failed conventional therapies. The product is approved in the indication in the EU. Abbott was off $0.58 to $62.24 on Thursday. ...